trending Market Intelligence /marketintelligence/en/news-insights/trending/2eedgi9bwnexgeajxf1nzq2 content esgSubNav
In This List

Halozyme appoints former Bristol-Myers exec as chief commercial officer

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Halozyme appoints former Bristol-Myers exec as chief commercial officer

Halozyme Therapeutics Inc. appointed Benjamin Hickey as chief commercial officer, effective Sept. 10.

The San Diego-based company said Hickey will build and execute the commercial strategy for its oncology portfolio, beginning with the investigational drug pegvorhyaluronidase alfa, or PEGPH20, if approved.

Hickey previously served as general manager for U.K. and Ireland at Bristol-Myers Squibb Co. During his 17-year career at Bristol-Myers, Hickey also served as vice president of marketing for immuno-oncology, where he led the commercialization of blockbuster cancer drug Yervoy and oversaw the launch preparedness of Opdivo, another blockbuster cancer drug.